Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643693 · ClinicalTrials.gov registry record · NA
User Acceptability of a Nicotine Lactate Delivery System (P3L)
A NA study, sponsored by Philip Morris Products S.A..
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT02643693: Completed NA study, sponsored by Philip Morris Products S.A..
NCT02643693 is a NA study that has completed, run by Philip Morris Products S.A.. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02643693, a NA study, has completed, sponsored by Philip Morris Products S.A..
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will provide an initial assessment of the acceptability of the Nicotine Lactate Delivery System (P3L) after ad libitum use and the ability of combustible cigarette (CC) smokers to use P3L to maintain their customary nicotine intake, in a manner comparable with their own brand of CC or the VUSE e-cigarette system.
Primary Outcome
For each ad libitum use session (P3L, VUSE, and CC), change from baseline plasma concentration of Nicotine/Cotinine was measured from two blood samples collected before product use (to provide baseline measures) and from two blood samples collected following product use (to show change from baseline).
Interventions
- OTHER CC
- OTHER P3L
- OTHER VUSE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-12 |
| Phase | NA |
What the finished NCT02643693 record still lists
NCT02643693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which CC is the first listed.
NCT02643693 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02643693 about?
NCT02643693 is a clinical study titled "User Acceptability of a Nicotine Lactate Delivery System (P3L)". This study will provide an initial assessment of the acceptability of the Nicotine Lactate Delivery System (P3L) after ad libitum use and the ability of combustible cigarette (CC) smokers to use P3L to maintain their customary nicotine intake, in a manner comparable with their own brand of CC or the...
What is the current status of trial NCT02643693?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2015-11. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02643693?
The interventions under investigation include: CC (OTHER), P3L (OTHER), VUSE (OTHER).
Who is sponsoring clinical trial NCT02643693?
This trial is sponsored by Philip Morris Products S.A., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02643693's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia